GlaxoSmithKline splashes out $1.4 billion on Aiolos Bio, Inc
Another day, another biopharmaucetical takeover by a major pharmaceutical company.
This time it's the turn of FTSE 100-listed GlaxoSmithKline, which is paying $1.4 billion for Aiolos Bio, Inc, a clinical-stage biopharmaceutical company developing treatments for respiratory and inflammatory conditions.
Below is the link to this morning if you would like to read all the details of the transaction:..
Register
Register for free to see rest of this article and all public articles from Betaville
Login / RegisterDate: Tuesday, 9 January 2024, 7:49 am